Three different doses of Niktimvo all had high rates of response among patients with recurrent or refractory ...

The graft versus host disease market is experiencing significant growth, driven by the ongoing adoption of branded therapies such as JAKAFI, IMBRUVICA, ORENCIA, and REZUROCK compared to off-label ...

A potentially life-saving cancer treatment is often referred to as the original immunotherapy and it helped pave the way for ...

Incyte (INCY) and Syndax Pharmaceuticals (SNDX) announced that results from the pivotal Phase 2 AGAVE-201 trial of ...

Panelists discuss how chronic graft-versus-host disease (cGVHD) differs from acute GVHD, its main challenges for patients, and its common symptoms and impact on daily life.

Chronic graft-versus-host disease (GVHD) remains a rare and unacceptably debilitating autoimmune-like syndrome that afflicts patients in whom a blood disorder or cancer is otherwise cured by means ...

The FDA has approved Incyte's axatilimab as a treatment for chronic graft-versus-host disease (GvHD), making it a companion to the company's Jakafi for the disorder. The US regulator has cleared ...

GVHD is a common and often fatal complication that can follow a bone marrow transplant, which occurs when the donated cells mount an immune response against the transplant recipient’s tissues ...

Niktimvo is the second US FDA-approved therapy for chronic GvHD in Incyte’s portfolio. The other product, Jakafi (ruxolitinib), raked in $2.6bn in sales last year, as per Incyte’s financials.

An ongoing clinical trial at MSK is now looking at whether lower doses of chemotherapy are as effective as higher doses at ...

One study showed similar OS and GVHD relapse-free survival (GRFS) with matched or mismatched unrelated donor (MUD, MMUD) transplants. In contrast, the second study showed lower overall survival ...